Astellas receives positive CHMP opinion for XOSPATA® (gilteritinib) as monotherapy for AML
Astellas Pharma announced the CHMP of the EMA has adopted a positive opinion recommending the oral once-daily therapy XOSPATA® (gilteritinib) as a monotherapy for treatment of adult patients who have relapsed or refractory (resistant to treatment) AML with a FLT3 mutation (FLT3mut+). September 20, 2019